99.7% PURITY LOT VL-2661-A CJC-1295 (No DAC)
A short-acting modified GRF(1-29) GHRH analog supplied as a 5 mg lyophilized vial for research into pulsatile growth-hormone release.
A short-acting modified GRF(1-29) GHRH analog supplied as a 10 mg lyophilized vial for research into pulsatile growth-hormone release.
- 1 × CJC-1295 (No DAC) 5mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
- 1 × CJC-1295 (No DAC) 10mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
About this compound
A short-acting modified GRF(1-29) GHRH analog supplied as a 5 mg lyophilized vial for research into pulsatile growth-hormone release.
- 5 mg lyophilized peptide per vial
- Modified GRF(1-29) GHRH analog (no DAC)
- Synthetic peptide, ≥99% purity
- Studied for pulsatile growth-hormone release
A short-acting modified GRF(1-29) GHRH analog supplied as a 10 mg lyophilized vial for research into pulsatile growth-hormone release.
- 10 mg lyophilized peptide per vial
- Modified GRF(1-29) GHRH analog (no DAC)
- Synthetic peptide, ≥99% purity
- Studied for pulsatile growth-hormone release
Why the lot matters
- Synthesized and tested per lot, never as a production-run average
- Certificate of Analysis published before the lot goes on sale
- Independent lab, contractually separate from manufacturing
What "research use only" means
This product is sold exclusively for in-vitro laboratory research. It is not evaluated by any medicines agency and is not intended for human or animal administration, diagnosis, treatment, or prevention of disease.
Technical data
Technical data
Current lot snapshot
Shipping
Reported use in research
CJC-1295 without DAC, also known as Modified GRF(1-29), is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH). It is designed to bind the GHRH receptor and, in research models, is investigated for its ability to stimulate the pituitary to release growth hormone. Because it lacks the Drug Affinity Complex found in the DAC variant, it is characterized in research by a comparatively short half-life. This short-acting profile has made it a subject of interest in studies examining pulsatile, rather than sustained, growth-hormone signaling. It is frequently used alongside GHRH-secretagogue research to explore receptor interactions in vitro and in animal models.
Reported findings
Research indicates that Modified GRF(1-29) can stimulate the release of growth hormone in preclinical and animal research models, producing brief, pulse-like elevations that contrast with the more prolonged activity reported for the DAC-modified version. Studies have investigated its receptor-binding behavior and its role in models of the growth-hormone axis. These reported characteristics have positioned it as a subject of interest in research into pulsatile GH secretion and GHRH-analog pharmacology. Findings to date remain confined to laboratory and animal research contexts.
Handling & safety
The safety and toxicological profile of CJC-1295 (No DAC) has not been fully characterized in research models, and comprehensive data remain limited. It is intended strictly for in-vitro and laboratory research and should be handled only by qualified personnel using appropriate personal protective equipment and standard laboratory practices. No conclusions regarding safety in humans or animals can be drawn from current research. Handlers should avoid inhalation, ingestion, and direct contact with skin or eyes.
Reconstitution
Recommended ratio
- 1 mL of bacteriostatic water per 10 mg vial
- Equivalent to 10 mg/mL (i.e. 1 mg per 10 units on a 100 U insulin syringe)
- Remove the plastic flip-off lid from the vial.
- Disinfect the rubber stoppers with alcohol wipes.
- Inject the diluent slowly down the inner wall of the vial to avoid foaming.
- Gently swirl the vial (never shake). Let it dissolve for about 10 minutes.
Storage
Unopened / before reconstitution
- Store at a stable temperature.
- Stable for 24 months.
- For long-term storage (2+ years), store at -20 °C.
Reconstituted solution
- Must be kept refrigerated.
- Avoid exposure to light and excessive heat.
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 3367.9 g/mol | PASS |
| Purity | HPLC (area %) | 99.7% | PASS |
| Net peptide content | Gravimetric | 5.00 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 3367.9 g/mol | PASS |
| Purity | HPLC (area %) | 99.6% | PASS |
| Net peptide content | Gravimetric | 5.01 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 3367.9 g/mol | PASS |
| Purity | HPLC (area %) | 99.7% | PASS |
| Net peptide content | Gravimetric | 10.02 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 3367.9 g/mol | PASS |
| Purity | HPLC (area %) | 99.6% | PASS |
| Net peptide content | Gravimetric | 10.03 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 3367.9 g/mol | PASS |
| Purity | HPLC (area %) | 99.5% | PASS |
| Net peptide content | Gravimetric | 10.02 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2661-A | Jul 2026 | 99.7% | TR-88717 | Active | |
| VL-2642-B | May 2026 | 99.6% | TR-88632 | Sold out |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2725-A | Jul 2026 | 99.7% | TR-88781 | Active | |
| VL-2706-B | May 2026 | 99.6% | TR-88696 | Sold out | |
| VL-2687-C | Mar 2026 | 99.5% | TR-88687 | Sold out |
